Abstract 1485P
Background
Patients (pts) diagnosed with metastatic cancer often experience a high symptom burden and diminished health-related quality of life (HRQOL), which can significantly impact their overall well-being. Physical activity (PA) has emerged as a promising intervention to alleviate symptoms and improve HRQOL in this population. This study examines the effects of a 12-week supervised remote PA program on symptom burden and health-related quality of life (HRQOL) in pts diagnosed with metastatic cancer.
Methods
This prospective study included eligible pts undergoing treatment for metastatic cancer. Initial assessments and weekly exercise guidance were provided to pts via WhatsApp. Proper home exercise techniques were demonstrated using the Vedius platform. The prescribed exercise regimen entailed 3 to 5 hours per week (4 to 6 days a week) of combined resistance and aerobic exercises. Outcome measures, including symptom burden (Edmonton Symptom Assessment System, ESAS, scale 0-90) and overall quality of life (Functional Assessment of Cancer Therapy-General, FACT-G, scale 0-108) were evaluated at baseline and after 12 weeks. Data analysis involved descriptive statistics and the linear mixed models.
Results
A total of 62 pts, with a median age of 68 years (range: 32-88), were enrolled in the study. Among the participants, 54.8% were female, 66.1% were white, and 61.3% were married, with 57.7% holding a college degree. The most prevalent cancer types included breast (24.2%), genitourinary (19.4%), lung (14.5%), and gynecological (14.5%). Over the study period, a significant improvement was observed in symptom burden (baseline mean=21.7, follow-up mean=7.8, P=0.001) and HRQOL (baseline mean=83.4, follow-up mean=95.4, P=0.001).
Conclusions
Our findings demonstrates that a 12-week supervised remote PA program has a significant positive impact on symptom burden and HRQOL in pts with metastatic cancer undergoing treatment. These findings underscore the potential benefits of incorporating PA interventions into the management of metastatic cancer, offering a promising avenue for improving patient outcomes and well-being.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1481P - A case-control study of drug-eluting microspheres and blank microspheres in bronchial artery embolization for hemoptysis in non-small cell lung cancer
Presenter: Tongguo Si
Session: Poster session 10
1482P - Percutaneous transhepatic biliary drainage (PTBD) for palliation of jaundice in patients of unresectable/disseminated carcinoma gall bladder with hilar block: Is it a worthwhile enterprise?
Presenter: Saurabh Galodha
Session: Poster session 10
1484P - Inflammatory patterns of ascites in patients with solid tumors
Presenter: Julia Berger
Session: Poster session 10
1486P - A personalized rehabilitation pilot program for improving QOL of unresectable metastatic lung cancer patients
Presenter: Shani Shilo
Session: Poster session 10
1487P - Telemonitoring system effectiveness for alleviating cancer pain in patients with advanced cancer
Presenter: Shiori Yoshida
Session: Poster session 10
1488P - Use of mobile app “SUPPORT+” to enhance community palliative care in advanced cancer patients: A feasibility study
Presenter: Wendy Chan
Session: Poster session 10
1489P - Factors influencing adherence to electronic patient-reported outcomes in palliative cancer care
Presenter: Sarah Gomes
Session: Poster session 10
1490P - Health-related quality of life of cancer patients on chemotherapy and its relationship with caregiver strain: A cross-sectional analytical study
Presenter: Herald Mapa
Session: Poster session 10
Resources:
Abstract
1491P - Palliative care of E-warm model for driver-gene-negative non-small cell lung cancer patients: A single-center randomized controlled trial
Presenter: Junhui Zhang
Session: Poster session 10
Resources:
Abstract